Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29680934 | 1.00 | KDM4E (0.33) | KDM4ELMNAALDH1A1MEN1PSMD14 | |
| SCHEMBL24528652 | 0.88 | KDM4E (0.32) | KDM4ELMNAALDH1A1 | |
| SCHEMBL29680746 | 0.85 | KDM4E (0.37) | KDM4ELMNAALDH1A1MEN1PSMD14 | |
| SCHEMBL24528512 | 0.85 | KDM4E (0.37) | KDM4ELMNAALDH1A1MEN1PSMD14 | |
| SCHEMBL29681045 | 0.83 | KDM4E (0.37) | KDM4ELMNAALDH1A1MEN1PSMD14 | |
| SCHEMBL24528596 | 0.83 | KDM4E (0.37) | KDM4ELMNAALDH1A1MEN1PSMD14 | |
| SCHEMBL29681200 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL24528685 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL24528695 | 0.82 | KDM4E (0.34) | KDM4ELMNAALDH1A1 | |
| SCHEMBL24528677 | 0.81 | KDM4E (0.34) | KDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129376-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-06-23 | — | — | WO | disclosed |